DOCSLIB.ORG

Antibiotic Shortages in Pediatrics MEDICATION SHORTAGES ARE INCREASING NATIONWIDE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antibiotic Shortages in Pediatrics MEDICATION SHORTAGES ARE INCREASING NATIONWIDE Ritu Banerjee, MD, PhD, a Cary W. Thurm, PhD, b Erin R. Fox, PharmD, c Adam L. Hersh, MD, PhDc Antibiotic Shortages in Pediatrics MEDICATION SHORTAGES ARE INCREASING NATIONWIDE Medication shortages are increasingly common and severe in the United States and are a serious health threat. Medication shortages occur when reduced supply of a drug influences how1 it is prepared, dispensed, or prescribed by pharmacies or providers. According to the US Food and Drug Administration (FDA), most shortages are caused by quality and 2 aVanderbilt University Medical Center, Nashville, Tennessee; manufacturing problems. Consequences of shortages include rationing bChildren’s Hospital Association, Lenexa, Kansas; and cUniversity of Utah, Salt Lake City, Utah limited supplies, delays in therapy,3 medication errors, use of less- efficacious alternatives, and death. Recently, critical drugs like sodium Drs Banerjee and Hersh conceptualized and designed chloride and amino acids have been on shortage, exacerbated by damage the study, drafted the initial manuscript, and reviewed to manufacturing plants by natural disasters like Hurricane Maria. and revised the manuscript; Dr Thurm collected the data, Although shortages have affected virtually all classes of medications, performed the initial analyses, and reviewed and revised the antimicrobial shortages are common and account for 15% of all drug manuscript; Dr Fox critically reviewed the manuscript for 1, 4 important intellectual content and revised the manuscript; shortages. and all authors approved the final manuscript as submitted ANTIMICROBIAL SHORTAGES CAN CAUSE HARM TO PATIENTS, AND THEIR and agree to be accountable for all aspects of the work. IMPACT ON CHILDREN IS NOT WELL STUDIED DOI: https:// doi. org/ 10. 1542/ peds. 2018- 0858 Accepted for publication Jul 30, 2018 Address correspondence to Ritu Banerjee, MD, PhD, Medication shortages can force clinicians to treat patients with Vanderbilt University Medical Center, 1161 21st Ave, Nashville, suboptimal therapy, which, in turn, can lead to poor outcomes. Examples TN 37232. E-mail: [email protected] relating to antimicrobial agents are when a penicillin shortage led PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098- to usePneumocystis of second-line jiroveci therapies for neurosyphilis, an intravenous 4275). trimethoprim-sulfamethoxazole shortage led to alternative therapies Copyright © 2018 by the American Academy of Pediatrics for infections, an acyclovir shortage led to use FINANCIAL DISCLOSURE: The authors have indicated they of alternative antiviral therapy for herpes encephalitis, and shortage have no financial relationships relevant to this article to of amikacin led to alternative antibiotic combinations for multidrug- disclose. resistant Gram-negative infections. Most infectious disease physicians FUNDING: No external funding. surveyed through the Emerging Infections Network reported that POTENTIAL CONFLICT OF INTEREST: Vizient pays Dr Fox’s antibiotic shortages had adversely affected patient outcomes in their1 affiliation, the University of Utah Drug Information Service, practice because of use of inferior, more-toxic, or costly alternatives. A to provide them with drug shortage data; no funds are recent shortage of piperacillin-tazobactam affected 88 of 107 hospitals directly paid to Dr Fox; and Drs Banerjee, Thurm, and Hersh have indicated they have no potential conflicts of interest to in the MedMined Clinic Research Database and led many institutions5 to disclose. prescribe alternativeClostridium antibiotics difficile in place of piperacillin-tazobactam. Hospitals that used more alternative antibiotics had higher rates of5 hospital-onset infection among adult patients. Few To cite: Banerjee R, Thurm CW, Fox ER, et al. Antibiotic evaluations of the impact of antimicrobial shortages on children have Shortages in Pediatrics. Pediatrics. 2018;142(5):e20180858 been performed. During a recent cefepime shortage, many pediatric institutions recommended the use of piperacillin-tazobactam in place of Downloaded from www.aappublications.org/news by guest on September 29, 2021 PEDIATRICS Volume 142, number 5, November 2018:e20180858 PEDIATRICS PERSPECTIVES ’ cefepime. At 1 children s hospital, this resulted in higher rates of acute kidney injury, which is associated with piperacillin-tazobactam and 6 vancomycin combination therapy. THE CEFOTAXIME SHORTAGE IS AN EXAMPLE OF A DRUG SHORTAGE THAT HAS NOT IMPACTED ALL INSTITUTIONS EQUALLY The number of companies supplying the third-generation cephalosporin, cefotaxime, has dwindled in recent years until only 1 company was supplying cefotaxime by 2016, as reported by the American Society of Health System Pharmacists FIGURE 1 7 Trends in use of cefotaxime and replacement antibiotics (ampicillin, ceftriaxone, ceftazidime, drug shortage Web site. Other cefepime, gentamicin, meropenem) among children hospitalized at 45 Pediatric Hospital Information companies that previously supplied System (PHIS) hospitals, 2014 through 2017. DOT, days of therapy (unpublished data). cefotaxime made a business decision to discontinue production because of an increase in the price of the raw materials. The single-remaining To examine the impact of the by the ongoing cefotaxime shortage, supplier was unable to keep up with cefotaxime shortage on hospitalized which has led to decreased use of children nationwide, we evaluated the demand for cefotaxime, leading to ’ cefotaxime in pediatric hospitals. a national shortage. cefotaxime use, a surrogate for However, when evaluated at drug availability, among children s the institutional level, there was The cefotaxime shortage has hospitals within the Pediatric significant variation in use (and by disproportionately affected infants, Hospital Information System implication, uneven availability) compared with older patients. This is network. The change in cefotaxime of cefotaxime among individual because a comparable cephalosporin, use was quantified for each hospital hospitals. ceftriaxone, that can be used in older between 2014 and 2015 and 2016 children, is generally not used in through quarter 2, 2017. Cefotaxime Variation in supplies of critical infants <2 months of age because use declined by 81%, from 28.8 to medications may be due to of increased risk of kernicterus 5.6 days of therapy per 1000 patient differences in patient populations, and calcium-ceftriaxone vascular days between 2014 and 2017, while drug use patterns, supply chain deposits. Because of limited supply, replacement antibiotic use increased management, existence of the American Academy of Pediatrics (Fig 1). However, the shortage was antimicrobial stewardship programs, recommended in February 2015 not experienced equally among that clinicians use ceftazidime hospitals. There was great variation and restrictions on use of short- in place of cefotaxime in infants in the extent to which cefotaxime use supply drugs. In 2011, the IMS <2 months of age with proven or declined, for all hospitalized children Institute for Healthcare Informatics suspected infections because of and for infants <60 days of age with a reported that some states are impacted more than others by Gram-negative8 bacilli, particularly diagnosis of meningitis (Fig 2). meningitis. Use of broad-spectrum CONCLUSIONS AND STRATEGIES TO drug shortages and attributed this therapies in place of cefotaxime may MITIGATE THE IMPACT OF MEDICATION to differences in per capita4 usage select for drug-resistant bacteria SHORTAGES of short-supply products. This ’ and have adverse consequences on variability in drug shortage impact patients microbiomes. At each of our seems unjust. More research is institutions, the cefotaxime shortage In the United States, medication needed to identify optimal strategies has led to restricted indications for shortages are common but may for preventing and managing its use and review of alternative not affect all hospitals equally. An shortages of critical medications, regimens. example of inequity is demonstrated which are likely to continue. Downloaded from www.aappublications.org/news by guest on September 29, 2021 2 BANERJEE et al ABBREVIATION FDA: US Food and Drug Administration REFERENCES 1. Quadri F, Mazer-Amirshahi M, Fox ER, et al. Antibacterial drug shortages from 2001 to 2013: implications for clinical practice [published correction appears in Clin Infect Dis. 2015;61(11):1769]. Clin Infect Dis. 2015;60(12):1737–1742 2. US Food and Drug Administration. A Review of FDA’s Approach to Medical Product Shortages. Washington, DC: US Department of Health and Human Services; 2011 3. Institute for Safe Medical Practices. Medication safety alert. Special issue: Drug shortages: National survey reveals high level of frustration, low level of FIGURE 2 Change in cefotaxime use for infants <60 days with a diagnosis of meningitis, between 2014 and safety. September 23, 2010. Available 2015 and 2016 through second quarter 2017, among 45 Pediatric Hospital Information System (PHIS) at: https:// www. ismp. org/ resources/ hospitals (unpublished data). special- issue- drug- shortages- national- survey- reveals- high- level- frustration- low- level. Accessed September 21, 2018 4. IMS Institute for Healthcare Informatics. The extent to which medication These include opportunities for Drug Shortages: A Closer Look at shortages have affected outcomes in more judicious antimicrobial use, Products, Suppliers, and Volume children should be better evaluated. wider stewardship efforts, and Volatility. Parsippany, NJ:
Load more

Recommended publications
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]
  • Penicillin Allergy Guidance Document
    Penicillin Allergy Guidance Document Key Points Background Careful evaluation of antibiotic allergy and prior tolerance history is essential to providing optimal treatment The true incidence of penicillin hypersensitivity amongst patients in the United States is less than 1% Alterations in antibiotic prescribing due to reported penicillin allergy has been shown to result in higher costs, increased risk of antibiotic resistance, and worse patient outcomes Cross-reactivity between truly penicillin allergic patients and later generation cephalosporins and/or carbapenems is rare Evaluation of Penicillin Allergy Obtain a detailed history of allergic reaction Classify the type and severity of the reaction paying particular attention to any IgE-mediated reactions (e.g., anaphylaxis, hives, angioedema, etc.) (Table 1) Evaluate prior tolerance of beta-lactam antibiotics utilizing patient interview or the electronic medical record Recommendations for Challenging Penicillin Allergic Patients See Figure 1 Follow-Up Document tolerance or intolerance in the patient’s allergy history Consider referring to allergy clinic for skin testing Created July 2017 by Macey Wolfe, PharmD; John Schoen, PharmD, BCPS; Scott Bergman, PharmD, BCPS; Sara May, MD; and Trevor Van Schooneveld, MD, FACP Disclaimer: This resource is intended for non-commercial educational and quality improvement purposes. Outside entities may utilize for these purposes, but must acknowledge the source. The guidance is intended to assist practitioners in managing a clinical situation but is not mandatory. The interprofessional group of authors have made considerable efforts to ensure the information upon which they are based is accurate and up to date. Any treatments have some inherent risk. Recommendations are meant to improve quality of patient care yet should not replace clinical judgment.
    [Show full text]
  • A New Trigger of Morbilliform Eruption in the Setting of Atypical Infectious
    A New Trigger of Morbilliform Eruption in the Setting of Atypical Infectious Mononucleosis Roxanne Rajaii, DO,* Megan Furniss, DO,** John Pui, MD,*** Brett Bender, DO**** *Dermatology Resident, PGY2, Beaumont Hospital - Farmington Hills, Farmington Hills, MI **Dermatology Resident, PGY4, Beaumont Hospital - Farmington Hills, Farmington Hills, MI ***Dermatopathologist, Beaumont Hospital - Farmington Hills, Farmington Hills, MI ****Dermatologist, Beaumont Hospital - Farmington Hills, Farmington Hills, MI Disclosures: None Correspondence: Roxanne Rajaii, DO; [email protected] Abstract Morbilliform eruptions, also commonly referred to as exanthematous or maculopapular drug eruptions, are the most common type of hypersensitivity reaction and can vary in etiology. Antibiotics are a common trigger, most notably amoxicillin or ampicillin in the setting of a concomitant and acute Epstein-Barr virus (EBV) infection. However, other antibiotics have been identified to cause a similar reaction in the setting of EBV. Cephalexin, a commonly used cephalosporin, is the only antibiotic in its class that has been implicated in causing such a phenomenon. We present a unique case of a morbilliform eruption in the setting of EBV secondary to the use of cefepime, further outlining the importance of conservative antibiotic use and awareness of such a reaction in this specific patient population, not only with penicillins but also with a wider spectrum of antibiotics. Introduction acquired pyelonephritis, as she had been admitted Work-up included the following laboratory tests: Epstein-Barr virus (EBV) infects more than a month prior to that for status asthmaticus. complete blood count, complete metabolic panel, 98% of the world’s adult population and is the Four days later, she presented with an urticarial anti-nuclear antibody, creatinine phosphate kinase, most common cause of infectious mononucleosis morbilliform rash.
    [Show full text]
  • Management of Penicillin and Beta-Lactam Allergy
    Management of Penicillin and Beta-Lactam Allergy (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Key Points • Beta-lactams are generally safe; allergic and adverse drug reactions are over diagnosed and over reported • Nonpruritic, nonurticarial rashes occur in up to 10% of patients receiving penicillins. These rashes are usually not allergic and are not a contraindication to the use of a different beta-lactam • The frequently cited risk of 8 to 10% cross-reactivity between penicillins and cephalosporins is an overestimate based on studies from the 1970’s that are now considered flawed • Expect new intolerances (i.e. any allergy or adverse reaction reported in a drug allergy field) to be reported after 0.5 to 4% of all antimicrobial courses depending on the gender and specific antimicrobial. Expect a higher incidence of new intolerances in patients with three or more prior medication intolerances1 • For type-1 immediate hypersensitivity reactions (IgE-mediated), cross-reactivity among penicillins (table 1) is expected due to similar core structure and/or major/minor antigenic determinants, use not recommended without desensitization • For type-1 immediate hypersensitivity reactions, cross-reactivity between penicillins (table 1) and cephalosporins is due to similarities in the side chains; risk of cross-reactivity will only be significant between penicillins and cephalosporins with similar side chains • Only type-1 immediate hypersensitivity to a penicillin manifesting as anaphylaxis, bronchospasm,
    [Show full text]
  • Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update
    Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update Aline Fuchsa, Julia Bielickia,b, Shrey Mathurb, Mike Sharlandb, Johannes N. Van Den Ankera,c a Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland b Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom c Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA WHO-Reviews 1 TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................................................... 3 1.1. Aims ......................................................................................................................................... 3 1.2. Background ............................................................................................................................. 3 1.2.1. Definition and diagnosis ................................................................................................. 3 Neonatal Sepsis ............................................................................................................................... 3 Paediatric Sepsis ............................................................................................................................. 4 Community versus hospital acquired sepsis .................................................................................. 5 1.2.2. Microbiology ..................................................................................................................
    [Show full text]
  • CEFOTAXIME Cefotaxime Sodium, Powder for Injection, Equivalent to Cefotaxime 500 Mg, 1 G and 2 G
    CEFOTAXIME Cefotaxime sodium, powder for injection, equivalent to Cefotaxime 500 mg, 1 g and 2 g PRESENTATION Cefotaxime is a white to slightly yellowish powder, which, when dissolved in Water for Injections B.P., forms a straw coloured solution given by intravenous or intramuscular administration. Each Cefotaxime 500 mg vial contains sterile cefotaxime sodium equivalent to cefotaxime 500 mg. Each Cefotaxime 1 g vial contains sterile cefotaxime sodium equivalent to cefotaxime 1 g. Each Cefotaxime 2 g vial contains sterile cefotaxime sodium equivalent to cefotaxime 2 g. Variations in the intensity of colour of the freshly prepared solution do not indicate change in potency or safety. USES Actions Cefotaxime is a semi-synthetic broad-spectrum bactericidal cephalosporin antibiotic. It is a other β-lactam antibiotic whose mode of action is inhibition of bacterial cell wall synthesis. Cefotaxime is exceptionally active in vitro against Gram-negative organisms sensitive or resistant to first or second generation cephalosporins. It is similar to other cephalosporins in activity against Gram-positive bacteria. Susceptibility Data Dilution or diffusion techniques – either quantitative minimum inhibitory concentration (MIC) or breakpoint, should be used following a regularly updated, recognised and standardised method e.g. NCCLS. Standardised susceptibility test procedures require the use of laboratory control micro-organisms to control the technical aspects of the laboratory procedures. A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the microbial compound in the blood reaches the concentrations usually achievable. Some strains of Pseudomonas aeruginosa (approximately 25%) and Bacteroides (approximately 43%) have in vitro MIC <16 mg/L.A report of “Intermediate” indicates that the results should be considered equivocal, and if the micro-organism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.
    [Show full text]
  • Ceftaroline in Complicated Skin and Skin-Structure Infections
    Infection and Drug Resistance Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Ceftaroline in complicated skin and skin-structure infections Paul O Hernandez1 Abstract: Ceftaroline is an advanced-generation cephalosporin antibiotic recently approved by Sergio Lema2 the US Food and Drug Administration for the treatment of complicated skin and skin-structure Stephen K Tyring3 infections (cSSSIs). This intravenous broad-spectrum antibiotic exerts potent bactericidal activity Natalia Mendoza2,4 by inhibiting bacterial cell wall synthesis. A high affinity for the penicillin-binding protein 2a (PBP2a) of methicillin-resistant Staphylococcus aureus (MRSA) makes the drug especially 1University of Texas School of Medicine at San Antonio, beneficial to patients with MRSA cSSSIs. Ceftaroline has proved in multiple well-conducted San Antonio, TX, 2Woodhull clinical trials to have an excellent safety and efficacy profile. In adjusted doses it is also recom- Medical and Mental Health Center, mended for patients with renal or hepatic impairment. Furthermore, the clinical effectiveness Brooklyn, NY, 3Department of Dermatology, University of Texas and high cure rate demonstrated by ceftaroline in cSSSIs, including those caused by MRSA Health Science Center at Houston, and other multidrug-resistant strains, warrants its consideration as a first-line treatment option 4 Houston, TX, USA; Department of for cSSSIs. This article reviews ceftaroline and its pharmacology, efficacy, and safety data to Dermatology, El
    [Show full text]
  • ESBL Disc Tests - Rev.2 / 19.06.2014 ESBL Disc Tests Disc Tests for Detection of ESBL-Producing Enterobacteriaceae
    © Liofilchem® - ESBL Disc Tests - Rev.2 / 19.06.2014 ESBL Disc Tests Disc tests for detection of ESBL-producing Enterobacteriaceae. DESCRIPTION Extended-spectrum β-lactamases (ESBLs) are enzymes hydrolyzing most penicillins and cephalosporins, including oxyimino- β-lactam compunds but not cephamycins and carbapenems. Most ESBLs belong to the Amber class A of β-lactamases and are inhibited by β-lactamases inhibitors: clavulanic acid, sulbatam and tazobactam. ESBL production has been observed mostly in Enterobacteriaceae, particularly Escherichia coli and Klebsiella pnuemoniae, but all other clinically-relevant Enterobacteriaceae species are also common ESBL-producers. In many areas, ESBL detection and characterization is recommended or mandatory for infection control purpose. ESBL detection involves two important steps. The first is a screening test with an indicator cephalosporin which looks for resistance or diminished susceptibility, thus identifying isolates likely to be harboring ESBLs. The second step is a confirmation test which evaluates the synergy between an oxyimino cephalosporin and clavulanic acid, distinguishing isolates with ESBLs from those that are resistant for other reasons. METHOD PRINCIPLE ESBL Disc Screening Disk-diffusion method for ESBL screening can be performed using cefpodoxime, ceftazidime, aztreonam, cefotaxime and ceftriaxone, according to EUCAST and/or CLSI guidelines (table 1). Since the affinity of ESBLs for different substrates is variable, the use of more than one of these agents for screening improves the sensitivity of detection. However, it is adequate to use the couple cefotaxime (or ceftriaxone) and ceftazidime. If only one drug can be used, cefpodoxime is the most sensitive indicator cephalosporin for detection of ESBL production may be used for screening.
    [Show full text]
  • Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides
    Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides a, b,c Luke F. Chen, MBBS (Hons), MPH, CIC, FRACP *, Donald Kaye, MD KEYWORDS Rifaximin Pharmacokinetics Pharmacodynamics Toxicity Polymyxins Aminoglycoside Rifampin The polymyxins, rifamycins, and the aminoglycosides may be considered special use antibacterial agents. They are all old agents and are rarely considered the drugs of choice for common bacterial infections. The polymyxins are increasingly important because of the continued emergence of multidrug resistant (MDR) gram-negative organisms, such as strains of Pseudomonas aeruginosa or carbapenemase-producing Enterobacteriaceae that are susceptible to few remaining drugs. Rifampin is only considered in the context of nonmycobacterial infections where its role is limited and sometimes controversial. Rifaximin is a new enteric rifamycin that is increasingly used for gastrointestinal infections such as trav- eler’s diarrhea and Clostridium difficile infections (CDIs). This article will also review the current role of aminoglycosides in nonmycobacterial systemic infections, with an emphasis on the use of single daily administration. POLYMYXINS The polymyxins were discovered in 1947. Although there are five known polymyxin molecules, sequentially named polymyxin A through polymyxin E, only two polymyxins are available for therapeutic use: polymyxin B and polymyxin E (colistin) (Table 1). Both polymyxin B and polymyxin E are large cyclic cationic polypeptide detergents A version of this article appeared in the 23:4 issue of the Infectious Disease Clinics of North America. a Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 102359, Hanes House, Durham, NC 27710, USA b Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA c 1535 Sweet Briar Road, Gladwyne, PA 19035, USA * Corresponding author.
    [Show full text]
  • MICU Antibiotics and Associated Drug Interactions
    MICU Antibiotics and Associated Drug Interactions Resistant Bacteria ► MICU patient are at risk for resistant organisms: § Recent hospitalizations § From a skilled nursing facility § Immunocompromised patients ►Transplant population ►Chronic steroid use Organisms of Concern ► Gram Negative organisms § Pseudomonas aeruginosa § Acinetobacter § Klebsiella pneumoniae ► ESBL § E.Coli ► ESBL ► Staph Aureus § MRSA ► Enterococcus faecalis & faecium § VRE Antibiotic Management Program (AMP) ► Patient safety initiative to address: § The infections related to C. difficile § Increasing antimicrobial resistance § Increasing antimicrobial cost Commonly Used Restricted Antibiotics ► Must call AMP to get an approval code (Full list on page 12 of Guide to Antimicrobial Chemotherapy) § Commonly used agents ► Ciprofloxacin ► Moxifloxacin ► Linezolid ► Ceftriaxone ► Ceftazidime ► Aztreonam ► Daptomycin ► Clindamycin ► Meropenem ► Imipenem ► Oral Vancomycin—unless you fill out a C.diff order set Not Restricted in the ICU ► Vancomycin ► Zosyn (piperacilin/tazobactam) ► Cefepime ► Aminoglycosides § Gentamicin § Tobramycin Pharmacodynamics ► Concentration dependant killing ► Goal: maximize the concentration § AUC/MIC ratio and Peak/MIC are predictors of efficacy § Antibiotics kill with increasing antibiotic concentrations at a greater rate and extent § Aminoglycosides ►Fluoroquinolones ►Metronidazole Pharmacodynamics ► Time dependent killing ► Goal: Maximize duration of exposure § T > MIC correlates best with efficacy ►Antibiotics kill bacteria at the same rate
    [Show full text]
  • Test Antibioticos.Pdf
    Lioflchem® Product Catalogue 2021 © Lioflchem® s.r.l. Est. 1983 Clinical and Industrial Microbiology Roseto degli Abruzzi, Italy Antibiotic discs in cartridge Description µg CLSI 1 EUCAST 3,4 Ref.* Amikacin AK 30 ✓ ✓ 9004 Amoxicillin AML 2 9151 Amoxicillin AML 10 ✓ 9133 Amoxicillin AML 25 9179 Amoxicillin AML 30 9005 Amoxicillin-clavulanic acid AUG 3 (2/1) ✓ 9191 Amoxicillin-clavulanic acid AUG 7.5 9255 Amoxicillin-clavulanic acid AUG 30 (20/10) ✓ ✓ 9048 Amoxicillin 10 + Clavulanic acid 0.1 AC 10.1 (10/0.1) 9278 ◆ Amoxicillin10 + Clavulanic acid 0.5 AC 10.5 (10/0.5) 9279 ◆ Amoxicillin 10 + Clavulanic acid 1 AC 11 (10/1) 9280 ◆ Ampicillin AMP 2 ✓ 9115 Ampicillin AMP 10 ✓ ✓ 9006 Ampicillin-sulbactam AMS 20 (10/10) ✓ ✓ 9031 Ampliclox (Ampicillin + Cloxacillin) ACL 30 (25/5) 9122 Azithromycin AZM 15 ✓ 9105 Azlocillin AZL 75 ✓ 9007 Aztreonam ATM 30 ✓ ✓ 9008 Bacitracin BA 10 units 9051 Carbenicillin CAR 100 ✓ 9009 Cefaclor CEC 30 ✓ ✓ 9010 Cefadroxil CDX 30 ✓ 9052 Cefamandole MA 30 ✓ 9014 Cefazolin KZ 30 ✓ 9015 Cefepime FEP 5 9219 Cefepime FEP 10 9220 Cefepime FEP 30 ✓ ✓ 9104 Cefepime + Clavulanic acid FEL 40 (30/10) ✓ 9 9143 Cefderocol FDC 15 9265 Cefderocol FDC 30 ✓ 9266 Cefxime CFM 5 ✓ ✓ 9089 Cefoperazone CFP 10 9210 ◆ Cefoperazone CFP 30 9016 Cefoperazone CFP 75 ✓ 9108 Cefotaxime CTX 5 ✓ 9152 Cefotaxime CTX 30 ✓ 9017 Cefotaxime + Clavulanic acid CTL 15 (5/10) ✓ 8 9257 ◆ Cefotaxime + Clavulanic acid CTL 40 (30/10) ✓ 9 9182 Cefotaxime + Clavulanic acid + Cloxacillin CTLC ✓ 9 9203 Cefotaxime + Cloxacillin CTC 230 (30/200) ✓ 9 9224 Cefotetan
    [Show full text]
  • Pharmacy Update: Truth and Consequences of Beta-Lactam Allergy Management
    Pharmacy Update: Truth and Consequences of Beta-Lactam Allergy Management Penicillin (PCN) Allergy Background o PCN allergy is the most common drug-class allergy reported - ~8-12% of patients self-report a PCN allergy - Reported anaphylactic reaction to PCN commonly precludes prescribers from using β-lactams in these patients o 80-90% of patients reporting a PCN allergy will have a negative response to PCN skin testing Impact of Penicillin Allergies o Penicillin “allergies” lead to: - More costly, less effective therapy o Longer length of stay, more medications used, more treatment failures - Worse clinical outcomes o Increased mortality, more treatment failures - 2nd and 3rd line antibiotics commonly substituted for β-lactams in patients with a penicillin “allergy” o Suboptimal use of fluoroquinolones, clindamycin, vancomycin, and aztreonam (e.g. vancomycin for MSSA) o Macy et al. J Allergy Clin Immunol: - Significantly more fluoroquinolone, clindamycin, and vancomycin use - 23.4% more C. difficile (95% CI: 15.6%-31.7%) - 14.1% more MRSA (95% CI: 7.1%-21.6%) - 30.1% more VRE infections (95% CI: 12.5%-50.4%) The Myth of Cross-Reactivity between Penicillins & Cephalosporins o The widely quoted cross-reactivity rate of 10% was originally reported in the 1960s, studies were flawed due to cephalosporins being frequently contaminated with penicillin o More recent observational studies have Table 1. FDA-approved Beta-lactam Antibiotics with Similar Side Chainsa found cross-reactivity rates between 0.17% Agent Agents with Similar Side Chains
    [Show full text]